Difference between revisions of "Team:DTU-Denmark"
| (2 intermediate revisions by one other user not shown) | |||
| Line 37: | Line 37: | ||
<i class="fa fa-bars"></i> | <i class="fa fa-bars"></i> | ||
</button> | </button> | ||
| − | <a class="navbar-brand navimg" href="#"><img src="https:// | + | <a class="navbar-brand navimg" href="#"><img src="https://static.igem.org/mediawiki/2015/b/b7/DTU-Denmark_dtulogo.png"></a> |
</div> | </div> | ||
<!-- Collect the nav links, forms, and other content for toggling --> | <!-- Collect the nav links, forms, and other content for toggling --> | ||
| Line 192: | Line 192: | ||
<li class="hidden-lg"> | <li class="hidden-lg"> | ||
<a href="https://igem.org" target="_blank" class="navimg"> | <a href="https://igem.org" target="_blank" class="navimg"> | ||
| − | <img src="https:// | + | <img src="https://static.igem.org/mediawiki/2015/a/af/DTU-Denmark_igemlogo.png"> |
</a> | </a> | ||
</li> | </li> | ||
| Line 210: | Line 210: | ||
| − | <div class="jumbotron hero" style="background-image: url(https:// | + | <div class="jumbotron hero" style="background-image: url(https://static.igem.org/mediawiki/2015/0/0b/DTU-Denmark_hero.jpg)"> |
<div class="igem-logo visible-lg"> | <div class="igem-logo visible-lg"> | ||
<a href="https://igem.org" target="_blank"> | <a href="https://igem.org" target="_blank"> | ||
| − | <img src="https:// | + | <img src="https://static.igem.org/mediawiki/2015/a/af/DTU-Denmark_igemlogo.png"> |
</a> | </a> | ||
</div> | </div> | ||
| Line 275: | Line 275: | ||
</h1> | </h1> | ||
| − | <p style="text-align: center;"><span style="font-size:72px;"><span class="fa fa-headphones" style="color:rgb(0, 0, 0);"></span></span></p> | + | <p style="text-align: center;"><span style="font-size:72px;"><span style="font-size:72px;"><span class="fa fa-headphones" style="color:rgb(0, 0, 0);"></span></span></span></p> |
| − | <p style="text-align: center;"> | + | <p style="text-align: center;">Listen to our podcast about our <a href="https://static.igem.org/mediawiki/2015/5/50/Podcast_project.mp4"><em>Project</em></a> or <a href="https://static.igem.org/mediawiki/2015/f/f5/Podcast_education.mp4"><em>Human practises</em></a></p> |
| − | <p | + | <p> </p> |
| + | |||
| + | <p><img alt="" src="https://static.igem.org/mediawiki/2015/5/5e/DTU-Denmark_gold.png" style="float:left; margin-right:10px;" /></p> | ||
| + | |||
| + | <p><br /> | ||
| + | DTU Denmark received a gold medal at the Giant Jamboree in Boston 2015 and a nomination for best educational human practises. Click on the headphones to hear our podcasts explaining our project and our human practises.</p> | ||
| + | |||
| + | <p>We also designed a <a href="https://2015.igem.org/Team:DTU-Denmark/Software">Wiki Wizard</a> that allows you to easily create and design wikis without knowing about HTML, CSS, and JavaScript. By using the shared editing mode, team members can edit the Wiki at the same time - just like Google Docs.</p> | ||
| + | |||
| + | <p> </p> | ||
| − | <p | + | <p>Nonribosomal peptides have important anti-bacterial, anti-cancer, and immunosuppressive biological activities. They are synthesized by modular, high molecular weight enzymes that assemble more than 500 different amino acid substrates in an assembly line manner. For this reason, synthetic biologists have tried to engineer these proteins and to switch modules to create analogs and novel natural products, but with little success. Despite being modular, the interactions between modules have evolved to be highly specific, making synthetic Non-Ribosomal Peptide Synthases (NRPS) a challenge to engineer. Instead of switching modules we introduced a recombination system targeting oligo integration in Bacillus subtilis. We used the recombineering system to alter the active sites determining substrate specificity, thereby creating variants of antibiotics. Our focus was the tyrocidine antibiotic, which cannot be used intravenously due to its toxicity. Our goal is to create new analogs through multiplex automated genome engineering to reduce toxicity.</p> |
| − | <p style="text-align: | + | <p style="text-align: center;"><img alt="" src="https://static.igem.org/mediawiki/2015/7/7d/DTU-Denmark_drawingpng.png" style="width: 625px; height: 378px;" /></p> |
<p> </p> | <p> </p> | ||
| Line 321: | Line 330: | ||
| − | + | <footer class="container"> | |
<div class="row"> | <div class="row"> | ||
<div class="col-md-2 col-md-offset-2"> | <div class="col-md-2 col-md-offset-2"> | ||
<a href="http://www.dtu.dk" target="_blank"> | <a href="http://www.dtu.dk" target="_blank"> | ||
| − | <img src="https:// | + | <img src="https://static.igem.org/mediawiki/2015/b/b7/DTU-Denmark_dtulogo.png" height="130px"> |
</a> | </a> | ||
</div> | </div> | ||
| Line 341: | Line 350: | ||
<div class="col-md-2"> | <div class="col-md-2"> | ||
<a href="https://igem.org" style="float:left" target="_blank"> | <a href="https://igem.org" style="float:left" target="_blank"> | ||
| − | <img src="https:// | + | <img src="https://static.igem.org/mediawiki/2015/a/af/DTU-Denmark_igemlogo.png" height="90px"> |
</a> | </a> | ||
</div> | </div> | ||
| Line 352: | Line 361: | ||
<div class="sponsorlogo"> | <div class="sponsorlogo"> | ||
<a href="http://www.lundbeckfonden.com/" target="_blank"> | <a href="http://www.lundbeckfonden.com/" target="_blank"> | ||
| − | <img src="/ | + | <img src="https://static.igem.org/mediawiki/2015/e/e2/DTU-Denmark_Lundbeckfonden.jpg"> |
</a> | </a> | ||
</div> | </div> | ||
| Line 358: | Line 367: | ||
<div class="sponsorlogo"> | <div class="sponsorlogo"> | ||
<a href="http://www.ottomoensted.dk" target="_blank"> | <a href="http://www.ottomoensted.dk" target="_blank"> | ||
| − | <img src="/ | + | <img src="https://static.igem.org/mediawiki/2015/3/35/DTU-Denmark_Ottomoensted.png"> |
</a> | </a> | ||
</div> | </div> | ||
| Line 364: | Line 373: | ||
<div class="sponsorlogo"> | <div class="sponsorlogo"> | ||
<a href="http://www.novonordiskfonden.dk/en" target="_blank"> | <a href="http://www.novonordiskfonden.dk/en" target="_blank"> | ||
| − | <img src="/ | + | <img src="https://static.igem.org/mediawiki/2015/5/5c/DTU-Denmark_NovoNordiskFonden_logo.png"> |
</a> | </a> | ||
</div> | </div> | ||
| Line 370: | Line 379: | ||
<div class="sponsorlogo"> | <div class="sponsorlogo"> | ||
<a href="https://dk.vwr.com/" target="_blank"> | <a href="https://dk.vwr.com/" target="_blank"> | ||
| − | <img src="/ | + | <img src="https://static.igem.org/mediawiki/2015/e/ea/DTU-Denmark_VWR.jpg"> |
</a> | </a> | ||
</div> | </div> | ||
| Line 376: | Line 385: | ||
<div class="sponsorlogo"> | <div class="sponsorlogo"> | ||
<a href="http://frisenette.dk" target="_blank"> | <a href="http://frisenette.dk" target="_blank"> | ||
| − | <img src="/ | + | <img src="https://static.igem.org/mediawiki/2015/c/c8/DTU-Denmark_Frisenette.jpg"> |
</a> | </a> | ||
</div> | </div> | ||
| Line 382: | Line 391: | ||
<div class="sponsorlogo"> | <div class="sponsorlogo"> | ||
<a href="http://www.in-vitro.dk/" target="_blank"> | <a href="http://www.in-vitro.dk/" target="_blank"> | ||
| − | <img src="/ | + | <img src="https://static.igem.org/mediawiki/2015/7/7c/DTU-Denmark_In_Vitro.jpg"> |
</a> | </a> | ||
</div> | </div> | ||
| Line 388: | Line 397: | ||
<div class="sponsorlogo"> | <div class="sponsorlogo"> | ||
<a href="https://dk.fishersci.com/dk/" target="_blank"> | <a href="https://dk.fishersci.com/dk/" target="_blank"> | ||
| − | <img src="/ | + | <img src="https://static.igem.org/mediawiki/2015/b/b4/DTU-Denmark_Fisher_Scientific.jpg"> |
</a> | </a> | ||
</div> | </div> | ||
| Line 394: | Line 403: | ||
<div class="sponsorlogo"> | <div class="sponsorlogo"> | ||
<a href="http://us.akg.com/akg-homepage-us.html" target="_blank"> | <a href="http://us.akg.com/akg-homepage-us.html" target="_blank"> | ||
| − | <img src="/ | + | <img src="https://static.igem.org/mediawiki/2015/9/9d/DTU-Denmark_AKG.png"> |
</a> | </a> | ||
</div> | </div> | ||
| Line 400: | Line 409: | ||
<div class="sponsorlogo"> | <div class="sponsorlogo"> | ||
<a href="http://www.macrogen.com/" target="_blank"> | <a href="http://www.macrogen.com/" target="_blank"> | ||
| − | <img src="/ | + | <img src="https://static.igem.org/mediawiki/2015/1/11/DTU-Denmark_Marcogen.jpg"> |
</a> | </a> | ||
</div> | </div> | ||
| Line 406: | Line 415: | ||
<div class="sponsorlogo"> | <div class="sponsorlogo"> | ||
<a href="http://www.snapgene.com/" target="_blank"> | <a href="http://www.snapgene.com/" target="_blank"> | ||
| − | <img src="/ | + | <img src="https://static.igem.org/mediawiki/2015/5/58/DTU-Denmark_Snapgene.png"> |
</a> | </a> | ||
</div> | </div> | ||
| Line 412: | Line 421: | ||
<div class="sponsorlogo"> | <div class="sponsorlogo"> | ||
<a href="https://www.neb.com/" target="_blank"> | <a href="https://www.neb.com/" target="_blank"> | ||
| − | <img src="/ | + | <img src="https://static.igem.org/mediawiki/2015/e/e0/DTU-Denmark_NEB_logo.png"> |
</a> | </a> | ||
</div> | </div> | ||
Latest revision as of 23:51, 20 November 2015
Project Description
Listen to our podcast about our Project or Human practises
DTU Denmark received a gold medal at the Giant Jamboree in Boston 2015 and a nomination for best educational human practises. Click on the headphones to hear our podcasts explaining our project and our human practises.
We also designed a Wiki Wizard that allows you to easily create and design wikis without knowing about HTML, CSS, and JavaScript. By using the shared editing mode, team members can edit the Wiki at the same time - just like Google Docs.
Nonribosomal peptides have important anti-bacterial, anti-cancer, and immunosuppressive biological activities. They are synthesized by modular, high molecular weight enzymes that assemble more than 500 different amino acid substrates in an assembly line manner. For this reason, synthetic biologists have tried to engineer these proteins and to switch modules to create analogs and novel natural products, but with little success. Despite being modular, the interactions between modules have evolved to be highly specific, making synthetic Non-Ribosomal Peptide Synthases (NRPS) a challenge to engineer. Instead of switching modules we introduced a recombination system targeting oligo integration in Bacillus subtilis. We used the recombineering system to alter the active sites determining substrate specificity, thereby creating variants of antibiotics. Our focus was the tyrocidine antibiotic, which cannot be used intravenously due to its toxicity. Our goal is to create new analogs through multiplex automated genome engineering to reduce toxicity.
